| 84.37 0.92 (1.1%) | 09-14 10:18 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 107.78 | 1-year : | 114.46 |
| Resists | First : | 92.28 | Second : | 98 |
| Pivot price | 91  |
|||
| Supports | First : | 83.04 | Second : | 69.08 |
| MAs | MA(5) : | 87.19 |
MA(20) : | 91.42 |
| MA(100) : | 103.31 |
MA(250) : | 97.97  |
|
| MACD | MACD : | -1.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 3.7 |
D(3) : | 14.8 |
| RSI | RSI(14): 38.7 |
|||
| 52-week | High : | 151.02 | Low : | 44.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CELC ] has closed above bottom band by 7.0%. Bollinger Bands are 43.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 87.4 - 88.24 | 88.24 - 88.74 |
| Low: | 81.48 - 82.56 | 82.56 - 83.21 |
| Close: | 82.22 - 83.97 | 83.97 - 85.02 |
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Fri, 11 Sep 2026
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Wed, 09 Sep 2026
Celcuity (CELC) Institutional Ownership 2026 $CELC - marketbeat.com
Tue, 01 Sep 2026
How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer - simplywall.st
Sat, 29 Aug 2026
What Could Celcuity (CELC) Gain If The FDA Clears REVTORPYK For Breast Cancer? - simplywall.st
Thu, 27 Aug 2026
Celcuity (CELC): Landmark Approval Collides With A Costly Launch - Yahoo Finance
Sun, 16 Aug 2026
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -72 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 4.893e+007 (%) |
| Held by Institutions | 2.972e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 433.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.83 |
| Qtrly Earnings Growth | -2.0848e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 196.2 |
| Price to Book value | -19.52 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.054e+007 |
| Forward Dividend | 1.115e+007 |
| Dividend Yield | 12560300% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|